Weber J T, Johnson R E
Epidemiology Research Branch, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
Clin Infect Dis. 1995 Apr;20 Suppl 1:S66-71. doi: 10.1093/clinids/20.supplement_1.s66.
To provide information for the formulation of treatment guidelines, we review recently published articles and abstracts on advances in the treatment of Chlamydia trachomatis genital infection. We ask specific questions about new treatments that are answered on the basis of the results of clinical trials and efficacy studies. New, potentially effective treatments for C. trachomatis genital infection include azithromycin and ofloxacin. Clinical studies indicate that the efficacy of these agents is equivalent to that of the current recommended agent doxycycline. Both azithromycin and ofloxacin are substantially more expensive than doxycycline. Azithromycin has the advantage of being given as a single dose, while doxycycline and ofloxacin are administered for 1 week. Issues of compliance, cost, and toxicity for specific patients should be considered when deciding whether to treat C. trachomatis genital infections with these agents.
为了给治疗指南的制定提供信息，我们回顾了最近发表的关于沙眼衣原体生殖道感染治疗进展的文章和摘要。我们针对新的治疗方法提出了一些具体问题，并根据临床试验和疗效研究结果进行解答。针对沙眼衣原体生殖道感染的新的、可能有效的治疗药物包括阿奇霉素和氧氟沙星。临床研究表明，这些药物的疗效与目前推荐药物多西环素相当。阿奇霉素和氧氟沙星的价格都比多西环素贵得多。阿奇霉素的优势在于只需单次给药，而多西环素和氧氟沙星则需给药1周。在决定是否使用这些药物治疗沙眼衣原体生殖道感染时，应考虑特定患者的依从性、成本和毒性问题。
